ESR1 and breast cancer: These findings are in stark contrast to observations in both male and female breast cancers, in which ERα sites devoid of FOXA1 were strongly promoter-enriched (Fig. 3a–c), suggesting the model systems currently used do not adequately capture the genomic distributions of ERα found in clinical samples.